Amyloid-Journal of Protein Folding Disorders

Papers
(The median citation count of Amyloid-Journal of Protein Folding Disorders is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Therapeutic effect of TTR siRNA on hereditary transthyretin amyloidosis (ATTRv) nephropathy215
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres190
Re-evaluation of Mayo 2004 and revised Mayo 2012 staging in patients with AL amyloidosis in the era of new therapies92
Changes in the amyloid editorial board members and in editor positions76
A second case of liraglutide-type localised amyloidosis59
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain40
The way to a man’s heart: prostate samples for the early detection of transthyretin cardiomyopathy34
Iatrogenic cerebral amyloid angiopathy rather than sporadic CAA in younger adults with lobar intracerebral haemorrhage28
Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial26
Oxidative conversion of transthyretin in formalin-fixed clinical amyloid samples results in the formation of the His90Asp and His90Asn variants20
In memoriam: Lawreen Connors, Ph.D.19
Whole tissue proteomic analyses of cardiac ATTR and AL unveil mechanisms of tissue damage19
Post-translational modification of amyloid a protein in patients with AA amyloidosis17
Diagnostic and prognostic contribution of DPD scintigraphy in transthyretin V30M cardiac amyloidosis17
Refining prognostication in systemic AL amyloidosis: limited value of dFLC14
Utilization and tolerance of beta-blockers among patients with AL amyloidosis14
Brain MRI in patients with V30M hereditary transthyretin amyloidosis14
A multicentric study of the disease risks and first manifestations in hereditary transthyretin amyloidosis (ATTRv): insights for an earlier diagnosis14
An updated AL-base reveals ranked enrichment of immunoglobulin light chain variable genes in AL amyloidosis13
A case of asymmetric insulin-derived localised amyloid deposition associated with long-acting insulin analog administration13
Metabolomics analysis for diagnosis and biomarker discovery of transthyretin amyloidosis13
Clinical and molecular insights into A97S variants in hereditary transthyretin amyloid polyneuropathy in South China12
Pupillometric findings in ATTRv patients and carriers: results from a single-centre experience12
High frequency of occult transthyretin and apolipoprotein AI–type amyloid in aortic valves removed by valve replacement for aortic stenosis12
Steep increase in the number of transthyretin-positive cardiac biopsy cases in Japan: evidence obtained by the nation-wide pathology consultation for the typing diagnosis of amyloidosis11
Prevalence and diagnostic value of extra-left ventricle echocardiographic findings in transthyretin-related cardiac amyloidosis11
Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis10
Mapping cellular response to destabilized transthyretin reveals cell- and amyloidogenic protein-specific signatures10
Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays9
Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee9
A novel substitution of proline (P32L) destabilises β2-microglobulin inducing hereditary systemic amyloidosis9
Neurological involvement in Ile68Leu (p.Ile88Leu) ATTR amyloidosis: not only a cardiogenic mutation8
Monitoring of cardiac transthyretin amyloid load by [99mTc]DPD scintigraphy: is it the end of the semi-quantitative evaluation?8
Possible transmission of leukocyte chemotactic factor 2 amyloidosis after interpopulational liver transplantation8
Comparison between tafamidis and liver transplantation as first-line therapy for hereditary transthyretin amyloidosis8
Gastrointestinal Amyloid Screening Study (GASS): is screening for amyloid in the gastrointestinal tract useful?7
Neurofilament light chain as a biomarker for hereditary ATTR amyloidosis − correlation between neurofilament light chain and nerve conduction study7
Involvement of bile acid in diarrhoea and therapeutic effect of colestimide in hereditary ATTR amyloidosis7
A rare occurrence and near miss! Should a TTR gene test be routinely performed for suspected ATTR-cardiomyopathy?7
Symptomatic SARS-CoV2 infection associated with high mortality in AA amyloidosis7
A novel approach for evaluating transthyretin kinetic stabilizers using plasma samples7
A novel APOA1 frameshift mutation Glu120Glyfs*60 with upper gastrointestinal involvement and an indolent course7
Neurofilament light chain kinetics as a biomarker for polyneuropathy in V122I hereditary transthyretin amyloidosis7
Amyloidosis from the patient perspective: the French daily impact of amyloidosis study6
Characterization of population genetic structure of hereditary transthyretin amyloidosis in Bulgaria6
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis6
T2-relaxometry in a large cohort of hereditary transthyretin amyloidosis with polyneuropathy6
Factors associated with financial toxicity in patients with transthyretin amyloidosis: results from Amyloidosis Research Consortium’s treatment affordability patient and caregiver survey6
Prevalence of amyloid in ligamentum flavum of patients with lumbar spinal stenosis5
Global patterns of amyloid typing: results of a survey by the International Society of Amyloidosis (ISA)5
Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial5
Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases5
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study5
AA amyloidosis in vertebrates: epidemiology, pathology and molecular aspects5
PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study5
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee5
Fibrinogen A α-chain amyloidosis associated with a rare frameshift pathogenic variant p.Arg547GlyfsTer215
Clinical and genetic features of AGel amyloidosis caused by novel gelsolin variant and its impact on cardiac function and conduction disorders5
The integration of genetically-regulated transcriptomics and electronic health records highlights a pattern of medical outcomes related to increased hepatic transthyretin expression5
Abnormal electrochemical skin conductance values in patients with AA amyloidosis4
Bone marrow amyloid: a comprehensive analysis of 1,469 samples, including amyloid type, clinical features, and morphologic distribution4
Longitudinal PET/CT imaging with iodine ( 124 I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis4
Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant4
Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging4
Development of late amyloid cardiomyopathy following liver transplantation for hereditary Val30Met transthyretin amyloidosis4
Role of complementarity-determining regions 1 and 3 in pathologic amyloid formation by human immunoglobulin κ1 light chains4
Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyl4
Fixed duration vs. prolonged duration treatment after first line therapy in patients with systemic light chain amyloidosis4
Absolute quantitative analysis of cardiac amyloidosis using SPECT/CT with 99mTc-pyrophosphate4
The role of serial 99mTc-DPD scintigraphy in monitoring cardiac transthyretin amyloidosis4
Survey of amyloidosis cases among different free-living wild and zoo animals3
Intra-familial variability of oculoleptomeningeal amyloidosis due to the ATTR I107M (c.381T > G) mutation: diagnostic challenges of a rare phenotype3
Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy3
Lysozyme amyloidosis—a report on a large German cohort and the characterisation of a novel amyloidogenic lysozyme gene variant3
Novel histopathological deposition patterns of EGF-containing fibulin-like extracellular matrix protein 1 amyloidosis: an autopsy case exhibiting a possible association between AEFEMP1 amyloidosis and3
Impact of tafamidis on myocardial strain in transthyretin amyloid cardiomyopathy3
Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease3
Gait abnormalities in older adults with transthyretin cardiac amyloidosis3
ATTR- and AFib amyloid - two different types of amyloid in the annular ligament of trigger finger3
Quantitative proteome profiling provides evidence of an activation of the complement cascade in ATTR amyloidosis3
Inappropriate use of technetium-99m pyrophosphate scanning for the evaluation of transthyretin amyloidosis3
Cardiac manifestations in Finnish gelsolin amyloidosis patients3
Somatostatin-derived amyloid deposition associated with duodenal neuroendocrine tumour (NET): a report of novel localised amyloidosis associated with NET3
Sequence diversity of kappa light chains from patients with AL amyloidosis and multiple myeloma3
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis2
Correction2
Usefulness of the Columbia score for predicting outcomes in patients with transthyretin amyloid cardiomyopathy. Analysis of the Galician registry of cardiac amyloidosis2
Characteristics of patients with autonomic dysfunction in the Transthyretin Amyloidosis Outcomes Survey (THAOS)2
Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study2
Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis2
Suboptimal response for AL amyloidosis: is it time for early switch? Experience from a single amyloid program2
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines2
Characterising diflunisal as a transthyretin kinetic stabilizer at relevant concentrations in human plasma using subunit exchange2
Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience2
In search of the most effective therapy for light chain amyloidosis2
Correction2
AA amyloidosis of unknown origin in New-Caledonia with focus on the association with gout: a consecutive case series of 20 patients2
Cardiac amyloidosis: the possibilities and challenges in the Ghanaian setting2
Quantitative sensory testing: a good tool to identify subclinical neuropathy in ATTRV30M amyloidosis patients?2
Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval2
Double pathogenic variant in an ATTRv patient with mixed phenotype1
Somatostatin-derived amyloidosis: a novel type of amyloidosis associated with well-differentiated somatostatin-producing neuroendocrine tumours1
AH amyloid neuropathy: a novel clinical phenotype confirmed by histopathology and mass spectrometry1
How well does liver span as part of the consensus criteria for liver involvement in AL amyloidosis perform?1
Obituary1
Binding of serum-derived amyloid-associated proteins to amyloid fibrils1
Transthyretin monomers: a new plasma biomarker for pre-symptomatic transthyretin-related amyloidosis1
Identification of calcitonin receptor-stimulating peptide 1-derived amyloid in a feline C-cell carcinoma1
Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival1
Immunoglobulin light-chain amyloidosis mimicking bulbar amyotrophic lateral sclerosis1
ELISA-4-amyloid: diagnostic accuracy of an ELISA panel for typing the four main types of systemic amyloidosis in subcutaneous abdominal fat tissue samples1
Prognostic value of CMR-derived extracellular volume in AL amyloidosis: a multicenter study1
A case of the iatrogenic transmission of vascular Aß40 amyloid1
Mass spectrometry-based proteomic analysis of proteins adsorbed by hexadecyl-immobilized cellulose bead column for the treatment of dialysis-related amyloidosis1
Anti-PEG antibodies associated with reduced therapeutic effect of patisiran in patients with hereditary transthyretin amyloidosis1
Clinical impact of beta-blocker withdrawal in transthyretin amyloid cardiomyopathy1
Previous surgery for lumbar spinal stenosis and association with amyloidosis and heart failure – A Danish nationwide study1
Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis1
Supportive care for systemic amyloidosis: International Society of Amyloidosis (ISA) expert panel guidelines1
Factors associated with changes in serum transthyretin after treatment with tafamidis and outcomes in transthyretin cardiac amyloidosis1
Hereditary transthyretin amyloidosis in Sweden: Comparisons between a non-endemic and an endemic region1
Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis1
Abnormal global longitudinal strain and reduced serum inflammatory markers in cardiac AL amyloidosis patients without significant amyloid fibril deposition1
0.079261064529419